| ￥3300 | |
| Z05904-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized TNFSF15, His, Human at 5μg/ml (100μl/well) on the plate can bind Human DR3, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 21.57 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in 20 mM PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized TNFSF15, His, Human, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Human DR3, hFc Tag with the EC50 of 0.19 μg/ml determined by ELISA. »
Immobilized TNFSF15, His, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-TNFSF15 Antibody, hFc Tag with the EC50 of 2.8 ng/ml determined by ELISA. »
The purity of TNFSF15, His, Human is greater than 85% and the molecular weight of this protein is around 60-90 kDa as determined by SEC-MALS. »
TNFSF15, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 90%. »
Human DR3, hFc Tag captured on CM5 Chip via Protein A can bind TNFSF15, His, Human, His Tag with an affinity constant of 4.09 nM as determined in SPR assay (Biacore T200). »
| Target Background | TNF superfamily member 15 (TNFSF15), a cytokine largely produced by vascular endothelial cells and a specific inhibitor of the proliferation of these same cells, can inhibit VEGF-induced vascular permeability in vitro and in vivo, and that death receptor 3 (DR3), a cell surface receptor of TNFSF15, mediates TNFSF15-induced dephosphorylation of VEGFR2. |
| Synonyms | TL1A; VEGI-251; TNFSF15; TL1; VEGI; VEGI192A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
